{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:56:15Z","timestamp":1762160175721},"reference-count":88,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,12]],"date-time":"2006-01-12T00:00:00Z","timestamp":1137024000000},"content-version":"vor","delay-in-days":682,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Recent evidence suggests that iron (Fe) and other metals play a role in a number of neurodegenerative diseases including Friedreich's ataxia, Alzheimer's disease, Huntington's disease, and Parkinson's disease. In this review, the role of Fe and other metals in the pathology of these conditions is assessed and the potential of Fe chelators for treatment is discussed. Lipophilic chelators have been designed that may be capable of crossing the blood\u2010brain barrier, a property lacking in desferrioxamine (DFO), a chelator in widespread clinical use. A far less commonly used chelator, clioquinol, has already shown activity <jats:italic>in vivo<\/jats:italic> in animal models and also in Alzheimer's disease patients. Considering that there is no effective treatment for many neurological diseases, the therapeutic use of lipophilic Fe chelators remains a potential strategy that requires investigation. In particular, we discuss the development of several series of aroylhydrazone chelators that could have high potential in the treatment of these diseases.<\/jats:p>","DOI":"10.1196\/annals.1306.026","type":"journal-article","created":{"date-parts":[[2004,4,23]],"date-time":"2004-04-23T03:27:51Z","timestamp":1082690871000},"page":"326-341","source":"Crossref","is-referenced-by-count":85,"title":["Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions"],"prefix":"10.1111","volume":"1012","author":[{"given":"DES R.","family":"RICHARDSON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,12]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90341-J"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199914020-00004"},{"key":"e_1_2_8_4_2","first-page":"743","article-title":"Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases","volume":"46","author":"Shoham S.","year":"2000","journal-title":"Cell. Mol. Biol."},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri N.F.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(03)00046-3"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","unstructured":"Burdo J.R. & J.R. Connor. 2002. Iron transport in the central nervous system.InMolecular and Cellular Iron Transport pp. 487\u2010508. Dekker. New York.","DOI":"10.1201\/9780824744175.ch20"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-4157(96)00014-7"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0098-2997(81)90003-0"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/41343"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0897-383"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/312162a0"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490180206"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/jcs.104.2.521","article-title":"Receptor\u2010mediated endocytosis of transferrin at the blood\u2010brain barrier","volume":"104","author":"Roberts R.L.","year":"1993","journal-title":"J. Cell. Sci."},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-3806(90)90103-6"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.30.20826"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M908846199"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041610119"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230631"},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V50.3.433.433","article-title":"Low molecular weight intracellular iron transport compounds","volume":"50","author":"Jacobs A.","year":"1977","journal-title":"Blood"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3360201"},{"key":"e_1_2_8_22_2","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood.V87.8.3477.bloodjournal8783477","article-title":"Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism","volume":"87","author":"Richardson D.R.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2728(96)00022-9"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8175"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17742"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.19.2789"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6139-5_33"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(02)00801-8"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/107385840200800107"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1042\/BST0300559"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01118.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10463"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/84859"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10253"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0704-6"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M105343200"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200101)16:1<23::AID-MDS1003>3.0.CO;2-2"},{"key":"e_1_2_8_38_2","first-page":"11","article-title":"Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease ? Novartis Found","volume":"235","author":"Andersen J.K.","year":"2001","journal-title":"Symp."},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122249699"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(84)80190-4"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11565-7"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)02096-X"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsbi.2000.4285"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(01)00317-8"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.21.12817"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0751219.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100175200"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M206428200"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8073293"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi990205o"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.092034699"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(02)00120-3"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(00)00494-9"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207435200"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021832302524"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051288"},{"key":"e_1_2_8_57_2","unstructured":"Masters C. 2002 (April 4). Seventh International Geneva\/Springfield Alzheimer's Symposium Geneva Switzerland."},{"key":"e_1_2_8_58_2","first-page":"101","article-title":"The neuropathology of subacute myelo\u2010optico\u2010neuropathy (SMONS) in the humans: with special reference to the quinoform intoxication","volume":"28","author":"Shiraki H.","year":"1975","journal-title":"Jpn. J. Med. Sci. Biol."},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401927"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.6.887"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(00)00067-4"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.8.4497"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3813"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.17.2025"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg096"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(02)00772-4"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5319.1709"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/84818"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1097-215"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/8.3.425"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01341-0"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1001"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.87.4.346"},{"key":"e_1_2_8_74_2","first-page":"685","article-title":"The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell","volume":"54","author":"Richardson D.R.","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(79)80111-8"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(01)00041-2"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.235"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb03771.x"},{"key":"e_1_2_8_79_2","first-page":"112","article-title":"Pyridoxal isonicotinoyl hydrazone: an effective chelator after oral administration","volume":"27","author":"Brittenham G.M.","year":"1990","journal-title":"Semin. Hematol."},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01142555"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-1693(00)80472-7"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-1693(00)80471-5"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(91)90192-Z"},{"key":"e_1_2_8_84_2","first-page":"660","article-title":"The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis","volume":"124","author":"Richardson D.R.","year":"1994","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(99)90173-7"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(98)90180-9"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejic.200390146"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007750100258"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1306.026","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1306.026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T09:09:48Z","timestamp":1695632988000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1306.026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1196\/annals.1306.026"],"URL":"https:\/\/doi.org\/10.1196\/annals.1306.026","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}